

# **Core Outcome Development for Carrier Screening (CODECS) Study: Towards a Core Outcome Set for Reproductive Genetic Carrier Screening**

**by Ebony Richardson**

Thesis submitted in fulfilment of the requirements for  
the degree of

**Doctor of Philosophy 95601 Genetic Counselling**

under the supervision of:

- ▶ Dr Chris Jacobs
- ▶ A/Prof Alison McEwen
- ▶ A/Prof Toby Newton-John

University of Technology Sydney  
Graduate School of Health, Faculty of Health

December 2022

 **Declaration of original authorship**

I, Ebony Richardson, declare that this thesis is submitted in fulfillment of the requirements for the award of the Doctor of Philosophy 95601 Genetic Counselling, in the Graduate School of Health at the University of Technology Sydney.

This thesis is wholly my own work unless otherwise referenced or acknowledged. In addition, I certify that all information sources and literature used are indicated in the thesis.

This document has not been submitted for qualifications at any other academic institution.

This research is supported by a UTS Research Excellence Scholarship.

Signature:

Production Note:  
Signature removed prior to publication.

Ebony Richardson

Date: 21/12/2022

 **Abstract**

**Background:** Reproductive genetic carrier screening (RGCS) provides prospective parents with information needed to understand their chance of having a child with a recessive genetic condition and informs reproductive decision-making. RGCS is well established in increased risk groups and is now transitioning to a population-based screening model with practice recommendations supporting its offer to all individuals planning a pregnancy or in the first trimester. Despite significant benefits being demonstrated in increased risk groups, there is little evidence regarding its impact when offered at population scale. Identifying and understanding which outcomes can meaningfully capture benefits and potential harms is key to informing the implementation of population-based RGCS. The Core Outcome Development for Carrier Screening (CODECS) study aims to establish a core outcome set (COS) for population-based RGCS. The COS is developed for use in any study offering RGCS at the population level, across various relevant study designs including observational studies and randomised controlled trials.

**Methods:** The steps of the CODECS study reported in this thesis are (1) a systematic review of quantitative studies evaluating RGCS, (2) a sequential systematic review of qualitative studies, (3) qualitative interviews with patient stakeholders, and (4) a Delphi survey of Australian and New Zealand stakeholders. These steps are per the framework established by the COMET initiative.

**Results:** The systematic review of quantitative studies identified 120 outcomes assessed in studies of RGCS (n=48). Outcome heterogeneity, bias and lack of patient-reported outcome measures were evident, and these provide a strong rationale for the development of a COS. The systematic review of qualitative studies (n=13) and qualitative interviews with patient stakeholders (n=15) identified outcomes of importance to patients that were not reflected in the quantitative literature, which indicates that further work is needed to ensure outcomes relevant to patients are incorporated into research. Collated outcomes were reviewed in a Delphi survey of 12 expert panellists. Eight outcomes reached consensus regarding their critical

importance for inclusion in all future studies and were used to define a preliminary COS: (1) carrier and couple detection rates, (2) uptake of prenatal diagnosis, (3) decision to continue or terminate affected pregnancies, (4) uptake of partner testing, (5) uptake of post-test genetic counselling, (6) reproductive decisions made by patients post-test and long term, (7) reproductive empowerment, and (8) affected individuals born to patients that accessed RGCS.

**Conclusion:** The development of a COS facilitates a structured and rigorous approach to identifying ‘what to measure’. This research identified significant gaps in the evidence base for population-based RGCS and highlighted the importance of assessing outcomes relevant to these gaps to inform implementation. The need for a patient-centred approach to outcome selection was central to the findings, with the incorporation of outcomes of importance to patients having the potential to enhance translation of research findings into clinical practice. A COS can address existing issues with research waste and ensure that future studies work towards a common goal of evidence-based practice recommendations. The findings presented here are crucial to inform the implementation of population-based RGCS and ensure best care for patients.

## Acknowledgements

Although a PhD is a journey embarked upon by an individual, it is by no means a solo undertaking. The hands and minds of many people have contributed to this body of work, and I am grateful to everyone who has supported me along the way.

I would like to thank my supervisory team. To Associate Professor Alison McEwen – you were the person who set me upon the path to a PhD, seeing the spark within me that was passionate about research and providing the opportunity to nurture and grow that spark into the work that is presented here. Your insightfulness and kindness have been appreciated more than you may know. To Professor Toby Newton-John – you were in many ways the wildcard addition to my supervisory panel, a new face from a different discipline. Your sage advice and big picture perspective has enriched our conversations and I am glad to have had you on my team. Most of all to my primary supervisor Dr Chris Jacobs – you have been the consistent and strong foundation from which I have grown my skills and competencies as a researcher. I will look fondly back on our many hours of conversation, although won't miss the early starts needed to manage our disparate time zones post-COVID and suspect that you will also appreciate having your nights back. I appreciate your time, insights, and thoughtfulness throughout my candidature.

I would like to acknowledge the broader academic context that supported me throughout my PhD. To the UTS Genetic Counselling Research Group – I appreciate your advice, support and constant encouragement. Special mentions to my fellow PhD students Ashley Crook and Steph White – you were in the trenches with me, experiencing all the lows and highs that come with a PhD and providing a constant source of comfort. I am glad for this experience to have brought us together and to be able to count you amongst my friends. Additional thanks to Ashley for your contribution to my published works. To the Graduate School of Health (GSH) and UTS broadly – you have created a space that values genetic counselling as a profession and nurtured the research-focus that is diversifying our role and contributing to a strong evidence-base regarding the value of our profession. I appreciate the numerous workshops and seminars available that boosted my knowledge and skills throughout my candidature. I am grateful for the financial support from the UTS Research Excellence Scholarship, which allowed me to undertake this PhD, and for the additional funds granted to me from the Faculty of Health and GSH to support open access publication of my work. I thank professional editor, Dr Laurel Mackinnon for

---

copyediting and proofreading services provided per the UTS Graduate Research Candidature Management, Thesis Preparation and Submission Procedures, and Guidelines for editing research theses from the Institute of Professional Editors.

I am appreciative of the research partners that joined the CODECS Study Advisory Group and contributed their time and expertise. Special mention to Dr Karine Manera – you provided much needed structure and guidance on the methods needed to develop a core outcome set. You were generous with your time and expertise and were a crucial part of establishing a strong foundation for this PhD at the outset.

I am endlessly grateful to the research participants that contributed to my studies, in particular the patient participants who shared their stories and were open and vulnerable about their experiences. Thank you for trusting me.

Lastly, many thanks to my ‘village’ of supporters. To Dr Jodie Ingles and the Clinical Genomics team based at the Centre for Population Genomics – you are my work family and have provided much needed balance between study, work and life throughout my candidature. I cannot express how thankful I am to be a part of your team. To my family – Mum, Dad and Jas – for your constant support and encouragement. Special mention to Mum for our Friday night debriefs and the many trays of warm brownies or muffins whenever I requested them. To my chosen family, my best friend Tyler – for the countless laughs and escapism of games night; George – for being my loyal furry companion; Aidan – for lending me your ear, loving generously, and always supporting my goals; and to the little life growing inside me – the most beautiful reason to have struggled through these last few months to submission.

## **Statement of format of thesis**

This thesis is presented as a thesis by compilation. It comprises an introduction in Chapter 1, presents the study design and methodology in Chapter 2, describes four separate studies in Chapters 3-6, and presents the discussion and conclusions in Chapter 7. I wrote all of the text in the thesis and revised it after feedback from my supervisors, Dr Chris Jacobs, A/Prof Alison McEwen and Prof Toby Newton-John. Chapters 2-5 provide, with permission, the accepted manuscripts of four peer-reviewed articles. Chapter 6 includes one manuscript currently under consideration and may not represent the final published form of this work. The referencing format for the manuscripts has been adapted where appropriate for consistency across the thesis and, where appropriate, spelling has been changed from US English to Australian English. The numbering and labelling of the tables, figures and supplementary files has been updated to be consistent across the thesis. Supporting information for each chapter is provided in the appendices.

## List of publications arising from this research

Richardson E, McEwen A, Newton-John T, Manera K, Jacobs C. The Core Outcome DEvelopment for Carrier Screening (CODECS) study: protocol for development of a core outcome set. *Trials*. 2021;22(1):480. doi: <https://doi.org/10.1186/s13063-021-05439-7>

Richardson E, McEwen A, Newton-John T, Crook A, Jacobs C. Systematic review of outcomes in studies of reproductive genetic carrier screening: Towards development of a core outcome set. *Genet Med*. 2021;24(1):1-14. doi: <https://doi.org/10.1016/j.gim.2021.08.005>

Richardson E, McEwen A, Newton-John T, Crook A, Jacobs C. Incorporating patient perspectives in the development of a core outcome set for reproductive genetic carrier screening: a sequential systematic review. *Eur J Hum Genet*. Mar 28 2022;30:756-765. doi: <https://doi.org/10.1038/s41431-022-01090-1>

Richardson E, McEwen A, Newton-John T, Crook A, Jacobs C. Outcomes of importance to patients in reproductive genetic carrier screening: A qualitative study to inform a core outcome set. *J Pers Med*. 2022;12(8):1310. doi: <https://doi.org/10.3390/jpm12081310>

Richardson E, McEwen A, Newton-John T, Crook A, Jacobs C. Defining core outcomes of reproductive genetic carrier screening: A Delphi survey of Australian and New Zealand stakeholders. 2022. Pre-print submitted to *In Review*.



## Statement of contribution of authors

- ▶ Contribution of graduate research student Ebony Richardson: lead author
- ▶ Contribution of Dr Chris Jacobs: primary supervisor, joint author
- ▶ Contribution of A/Prof Alison McEwen: co-supervisor, joint author
- ▶ Contribution of Prof Toby Newton-John: co-supervisor, joint author
- ▶ Contribution of Dr Ashley Crook: joint author
- ▶ Contribution of Dr Karine Manera: joint author

### Signatures:

Production Note:  
Signature removed prior to publication.

-----  
Ebony Richardson

Production Note:  
Signature removed prior to publication.

-----  
A/Prof Alison McEwen

Production Note:  
Signature removed prior to publication.

-----  
Dr Ashley Crook

Production Note:  
Signature removed prior to publication.

-----  
Dr Chris Jacobs

Production Note:  
Signature removed prior to publication.

-----  
Prof Toby Newton-John

Production Note:  
Signature removed prior to publication.

-----  
Dr Karine Manera

## Dissemination of research

### Accepted for oral presentation – peer reviewed

Richardson E (2021) Results of a systematic review and protocol for further projects. Paper presented at: UTS Faculty of Health conference; November 24<sup>th</sup>, 2021; Sydney, Australia.

### Accepted for poster presentation – peer reviewed

Richardson E, McEwen A, Newton-John T, Manera K, Crook A, Jacobs C. (2020) The Core Outcome Development for Carrier Screening (CODECS) Study: Systematic review of outcomes in studies implementing reproductive genetic carrier screening. Paper presented at: Human Society of Australasia (HGSA) annual scientific meeting; November 24<sup>th</sup>, 2020; Virtual conference.

Richardson E (2021) Is research wasteful? Making a case for core outcome sets. Paper presented at: UTS Faculty of Health 3 Minute Thesis Competition; June 15<sup>th</sup>, 2021; Sydney, Australia.

Richardson E, McEwen A, Newton-John T, Crook A, Jacobs C. (2021) Incorporating the patient perspective: Systematic review of outcomes in qualitative studies evaluating the patient experience of reproductive genetic carrier screening. Paper presented at: Human Society of Australasia (HGSA) annual scientific meeting; August 16<sup>th</sup>, 2021; Adelaide, Australia.

Richardson E., McEwen A., Newton-John T., Manera K., Crook A., Jacobs C. (2021) Developing a core outcome set for reproductive genetic carrier screening: A new approach to understanding outcomes in genetics. Paper presented at: The World Congress on Genetic Counselling; 27<sup>th</sup> October, 2021; Virtual conference.

Richardson E., McEwen A., Newton-John T., Crook A., White S., Jacobs C. (2022) The Core Outcome Development for Carrier Screening (CODECS) Study: Results of an AUS/NZ Pilot Delphi Survey. Paper presented at: Human Society of Australasia (HGSA) annual scientific meeting; November 26<sup>th</sup>, 2021; Perth, Australia.

**Awarded the Australasian Society of Genetic Counsellors (ASGC) prize for best poster presentation**

### Invited oral presentations

*NSW Genetic Counsellor Quarterly Meeting 2019*

Richardson E. (2019) Is there a role for core outcome sets in genetic counselling research? An overview of outcomes and thoughts regarding reproductive carrier screening.

*Australasian Society of Genetic Counsellors Monthly Webinar Series 2022*

Richardson E. (2022) Translating research findings into clinical practice: Potential benefits of a core outcome set.

## **Table of contents**

Declaration of original authorship .....	i
Abstract .....	ii
Acknowledgements.....	iv
Statement of format of thesis.....	vi
List of publications arising from this research.....	vii
Statement of contribution of authors .....	viii
Dissemination of research.....	ix
List of appendices.....	xvi
List of figures.....	xviii
List of summary boxes .....	xix
List of tables.....	xx
List of abbreviations.....	xxi
Glossary of terms .....	xxiii
<b>Chapter 1: Introduction .....</b>	<b>1</b>
1.1 Thesis overview .....	1
1.2 Chapter overview .....	1
1.3 Genetic counselling .....	1
1.3.1 Genetic counselling as a profession .....	1
1.3.2 Relevance of my profession to this thesis.....	3
1.4 Reproductive genetic carrier screening .....	4
1.4.1 Purpose of RGCS .....	4
1.4.2 History of RGCS .....	4
1.4.3 Definition and scope of RGCS.....	5
1.4.4 Current context of RGCS.....	6
1.5 Practice guidelines and recommendations .....	7
1.5.1 Support for the offer of RGCS .....	7
1.5.2 Limitations of current recommendations.....	8
1.6 Introduction to core outcome set development .....	13
1.6.1 Addressing systemic issues in outcomes research.....	13
1.6.2 The Core Outcome Measures in Effectiveness Trials (COMET) initiative .....	14
1.7 Overview of the thesis.....	16
1.7.1 Chapter structure .....	16

1.7.2 Steps of the CODECS study presented in this thesis .....	18
1.7.3 Aims of the CODECS study .....	19
1.7.4 Guiding principles of the CODECS study .....	19
1.7.5 Setting .....	20
1.7.6 Consultation.....	20
1.8 References.....	21
<b>Chapter 2: Research methods.....</b>	<b>28</b>
2.1 Chapter overview .....	28
2.2 Abstract.....	28
2.3 Methods/design .....	29
2.3.1 Scope .....	29
2.3.2 Step I – Systematic review of outcomes reported in quantitative studies on reproductive genetic carrier screening .....	32
2.3.3 Step II: Systematic review of outcomes reported in qualitative studies on reproductive genetic carrier screening .....	33
2.3.4 Step III: Semi-structured patient focus groups/interviews .....	35
2.3.5 Step IV: Delphi survey.....	37
2.3.6 Step V: Consensus meeting.....	40
2.4 Discussion .....	42
2.5 Amendments to the protocol.....	42
2.6 References.....	43
<b>Chapter 3: Systematic review of quantitative studies .....</b>	<b>46</b>
3.1 Chapter overview.....	46
3.2 Abstract .....	46
3.3 Introduction.....	47
3.4 Material and methods.....	48
3.4.1 Search strategy .....	48
3.4.2 Study selection .....	49
3.4.3 Quality assessment and risk of bias.....	49
3.4.4 Data extraction .....	49
3.4.5 Data analysis .....	50
3.5 Results.....	51
3.5.1 Search strategy .....	51
3.5.2 Study characteristics.....	51

3.5.3 Quality assessment and risk of bias.....	51
3.5.4 Study designs .....	52
3.5.5 Frequency of study outcomes.....	54
3.5.6 Outcome domains and heterogeneity.....	54
3.5.7 Measurement methods .....	55
3.5.8 Criteria for assessment of genetic screening programs <sup>26</sup> .....	57
3.6 Discussion.....	59
3.7 Limitations .....	64
3.8 Conclusion .....	64
3.9 Summary of supporting data available in Appendix A .....	64
3.10 References.....	65
<b>Chapter 4: Systematic review of qualitative studies .....</b>	<b>76</b>
4.1 Chapter overview .....	76
4.2 Abstract.....	76
4.3 Introduction.....	77
4.4 Material and methods .....	78
4.4.1 Search strategy.....	78
4.4.2 Study selection.....	79
4.4.3 Quality assessment and risk of bias .....	79
4.4.4 Data extraction.....	79
4.4.5 Data analysis.....	80
4.5 Results.....	81
4.5.1 Search strategy.....	81
4.5.2 Study characteristics.....	81
4.5.3 Quality assessment and risk of bias.....	81
4.5.4 Outcomes identified in qualitative studies of RGCS .....	82
4.5.5 Findings of the sequential review.....	86
4.6 Discussion .....	88
4.7 Limitations.....	93
4.8 Conclusion .....	94
4.9 Summary of supporting data available in Appendix B .....	94
4.10 References.....	95
<b>Chapter 5: Stakeholder consultation .....</b>	<b>100</b>
5.1 Chapter overview .....	100

5.2 Abstract .....	100
5.3 Graphical abstract .....	101
5.4 Introduction .....	102
5.5 Materials and methods .....	103
5.5.1 Theoretical paradigm .....	103
5.5.2 Recruitment and patient and public involvement.....	104
5.5.3 Inclusion and exclusion criteria.....	105
5.5.4 Participant selection .....	105
5.5.5 Data collection .....	105
5.5.6 Data analysis .....	107
5.6 Results.....	107
5.6.1 Participant characteristics.....	107
5.6.2 Aim 1: To explore the themes underlying participant interviews and how these inform our understanding of outcomes that are important to prospective parents accessing RGCS.....	109
5.6.3 Aim 2: To explore the role of including qualitative consultation with patient stakeholders in the development of a COS.....	113
5.7 Discussion.....	115
5.8 Conclusion .....	121
5.9 Limitations.....	121
5.10 Research team.....	122
5.11 Additional supporting information .....	122
5.11.1 Theoretical underpinning of the study design .....	122
5.11.2 Statement of reflexivity .....	124
5.12 Summary of supporting data available in Appendix C .....	126
5.13 References.....	127
<b>Chapter 6: Consensus process.....</b>	<b>133</b>
6.1 Chapter overview.....	133
6.2 Abstract .....	133
6.3 Introduction.....	134
6.4 Materials and methods .....	135
6.4.1 Study design .....	135
6.4.2 Participant selection .....	136
6.4.3 Compiling outcomes.....	137

6.4.4 Piloting Delphi questions .....	137
6.4.5 Data collection .....	138
6.4.6 Data analysis .....	139
6.5 Results .....	141
6.5.1 Participant characteristics.....	141
6.5.2 Distribution of rankings from Round 1 and inclusion in Round 2 .....	141
6.5.3 Distribution of Round 2 rankings and definition of tiers of consensus.....	149
6.5.4 Tier 1 outcomes and definition of a preliminary COS.....	152
6.5.5 Lower tiers of consensus.....	153
6.5.6 Outcomes with no agreement .....	153
6.6 Discussion.....	154
6.7 Limitations .....	157
6.8 Conclusion .....	157
6.9 Summary of supporting data available in Appendix D .....	157
6.10 References.....	158
<b>Chapter 7: Synthesis of findings and discussion of the implications for clinical practice and future research.....</b>	<b>163</b>
7.1 Chapter overview.....	163
7.2 Addressing study aims .....	163
7.2.1 Primary aim 1: To establish an evidence base to support the development of a core outcome set for reproductive genetic carrier screening.....	163
7.2.2 Primary aim 2: To explore the patient experience of reproductive genetic carrier screening and engage in a co-design process to understand the outcomes of importance to patients .....	164
7.2.3 Primary aim 3 (amended): To understand the level of consensus on the core outcomes that should be measured by all future studies of RGCS.....	166
7.3 Key findings .....	166
7.3.1 Key finding 1 - Outcomes of importance to patients are not currently being measured in RGCS studies .....	168
7.3.2 Key finding 2 - Future studies should explore potential adverse outcomes to inform evidence-based practice recommendations .....	170
7.3.3 Key finding 3 - A consensus definition of utility is needed to meaningfully capture benefits of RGCS.....	173

7.3.4 Key finding 4 - Core outcome development methodology can address key issues with research quality and waste .....	176
7.4 Conclusion .....	178
7.5 Strengths and limitations .....	178
7.5.1 Strengths.....	179
7.5.2 Limitations.....	181
7.6 Implications for research and clinical practice.....	182
7.6.1 Implications for future research.....	182
7.6.2 Implications for clinical practice .....	183
7.6.3 Next steps of the CODECS study .....	184
7.6.4 Contributions to the field.....	185
7.7 References .....	186



## List of appendices

Appendix A – Supporting information for Chapter 3 .....	195
Supplementary material A.1: Illustrative search strategy .....	196
Supplementary material A.2: COMET/CODECS Taxonomy Version 1.0 .....	197
Supplementary material A.3: Summary of included studies .....	200
Supplementary material A.4: Risk of bias assessment .....	207
Supplementary material A.5: List of outcomes extracted from quantitative studies...	208
Supplementary material A.6: Block diagram of outcomes reported per study.....	214
Supplementary material A.7: Outcome measurement methods .....	218
Appendix B – Supporting information for Chapter 4 .....	230
Supplementary material B.1: Illustrative search strategy.....	231
Supplementary material B.2: COMET/CODECS taxonomy version 1.1.....	232
Supplementary material B.3: Summary of included studies.....	236
Supplementary material B.4: Risk of bias assessment. ....	239
Supplementary material B.5: List of outcomes extracted from qualitative studies .....	240
Supplementary material B.6: Block diagram of outcomes reported per study .....	245
Appendix C – Supporting information for Chapter 5.....	253
Supplementary material C.1: Guidance informed study design.....	253
Supplementary material C.2 – Social media expressions of interest .....	254
Supplementary material C.3: Eligibility and demographic survey .....	256
Supplementary material C.4: Emails to respondents/participants .....	259
Supplementary material C.5: Participant information sheet .....	262
Supplementary material C.6: COMET/CODECS taxonomy version 1.2 .....	264
Supplementary material C.7: Interview schedule .....	267
Supplementary material C.8: Example virtual whiteboard .....	271
Supplementary Material C.9 – Methodological feedback from participants .....	271
Appendix D – Supporting information for Chapter 6 .....	274
Supplementary material D.1: Protocol changes for the AUS/NZ Delphi process and implications for an international Delphi process .....	275
Supplementary material D.2: Email invitations .....	277
Supplementary material D.3: Participant information sheet.....	280
Supplementary material D.4: Guidance for participants document – Round 1.....	283
Supplementary material D.5: Round 1 Delphi survey .....	287

Supplementary material D.6: Outcomes excluded from Round 2 .....	315
Supplementary material D.7: Outcome eligible for inclusion in Round 2 .....	318
Supplementary material D.8: Outcomes combined for Round 2.....	322
Supplementary material D.9: Guidance for participants document - Round 2.....	324
Supplementary material D.10: Round 2 Delphi survey.....	326
Supplementary material D.11: List of outcomes per tier following Round 2 .....	368

 **List of figures**

Figure 1: Overview of the steps involved in developing a COS. ....	15
Figure 2: Diagrammatic overview of the thesis with aims .....	17
Figure 3: Study overview diagram.....	31
Figure 4: PRISMA diagram for quantitative studies .....	52
Figure 5: Summary of outcomes per domain .....	56
Figure 6: Domain frequency and outcome heterogeneity .....	57
Figure 7: PRISMA diagram for qualitative studies.....	82
Figure 8: Outcomes domain across studies .....	84
Figure 9: Proportion of studies reporting per CODECS outcome domains .....	87
Figure 10: Interview schedule overview with examples .....	106
Figure 11: Block diagram illustrating the CODECS outcome domains represented across interviews .....	115
Figure 12: Positioning of the researcher.....	124
Figure 13: Compiling outcomes for inclusion in Round 1.....	138
Figure 14: Reduction in outcomes based on Round 1 results .....	142
Figure 15: Distribution of rankings from Round 1.....	143
Figure 16: Distribution of rankings in Round 2 .....	149
Figure 17: Preliminary COS.....	152
Figure 18: Integrated results matrix .....	167
Figure 19: Overview of the steps involved in developing a COS correlated with corresponding steps of the CODECS Study.....	180
Figure 20: International representation across studies .....	181

## **List of summary boxes**

Box 1: Significance of systematic review findings.....	59
Box 2: Comparison of key findings from sequential systematic reviews of quantitative and qualitative studies.....	88

## List of tables

Table 1: Summary of evidence levels in recent practice recommendations .....	9
Table 2: Evaluation of current practice recommendations against NHMRC standards for guideline development .....	10
Table 3: Summary of amendments to the published protocol .....	43
Table 4: Characteristics of included studies .....	53
Table 5: Characteristics of included studies.....	83
Table 6. Characteristics of interview participants.....	108
Table 7: Characteristics of Delphi survey participants .....	141
Table 8: Round 1 rankings.....	144
Table 9: Round 2 rankings.....	150



## List of abbreviations

<b>Abbreviation</b>	<b>Term</b>
ACCE	Analytic Validity, Clinical Validity, Clinical Utility and Ethical, legal and social implications
ACMG	American College of Medical Genetics
ACOG	American College of Obstetricians and Gynaecologists
ASGC	Australasian Society of Genetic Counsellors
AUS	Australia
CGS	Clinical genetic services
CODECS study	Core Outcome Development for Carrier Screening study
COMET	Core Outcomes Measures in Effectiveness Trials
COREQ	Consolidated Criteria for Reporting Qualitative Research
COS	Core outcome set
COS-STAD	Core Outcome Set-Standards for Development
COS-STAP	Core Outcome Set-Standardised Protocol Items
COS-STAR	Core Outcome Set-Standards for Reporting
CVS	Chorionic villus sampling
FOCUS-GC	Framework for Outcomes of Clinical Communication Services in Genetic Counseling
GCOS-24	Genetic Counselling Outcomes Scale
GOS	Genomic Outcomes Scale
GP	General practitioner
GRADE	Grading of Recommendations, Assessment, Development and Evaluations
GSH	Graduate School of Health
HGSA	Human Genetics Society of Australasia
HREC	Human Research Ethics Committee
HTA	Health technology assessment
IVF	In vitro fertilisation
MCH	Mean corpuscular haemoglobin
MCV	Mean corpuscular volume
MMIC	Multi-Dimensional Measure of Informed Choice
NHMRC	National Health and Medical Research Council

NIHR	National Institute for Health Research
NSGC	National Society of Genetic Counselors
NZ	New Zealand
OMERACT	Outcome Measures in Rheumatology
ORBIT	Outcome Reporting Bias in Trials
PACER	Patient-Centred Research Network
PCORI	Patient-Centered Outcomes Research Institute
PGD	Preimplantation genetic diagnosis
PICO	Patient/Population, Intervention, Comparison and Outcomes
PND	Prenatal diagnosis
PRISMA	Preferred Reporting Items for Systematic Reviews and Meta-Analyses
PROSPERO	International Prospective Register of Systematic Reviews
RANZCOG	Royal Australian and New Zealand College of Obstetricians and Gynaecologists
RCT	Randomised controlled trial
RGCS	Reproductive genetic carrier screening
SAG	Study Advisory Group
SMG	Study Management Group
SOGC-CCMG	Society Of Obstetricians and Gynaecologists of Canada Genetics Committee and the Canadian College of Medical Geneticists Clinical Practice Committee
SONG	Standardised Outcomes in Nephrology
SPOR	Strategy for Patient-Oriented Research
TOP	Termination of pregnancy
UAE	United Arab Emirates
UK	United Kingdom
USA	United States of America
UTS	University of Technology Sydney



## Glossary of terms

Term	Definition
Consensus-based practice recommendations	Practice recommendations that have drawn evidence primarily from the opinions of key stakeholders; often due to a lack of available empirical evidence to inform the recommendation.
Couples	The term 'couple(s)' is used throughout this thesis to describe a broad range of family structures with a desire to have children. The phrasing 'couple' refers to the genetic parents of a current or future planned pregnancy
Evidence-based practice recommendations	Practice recommendations informed by a body of empirical evidence that can be trusted to guide practice
Genetic counselling*	The National Society of Genetic Counselors (NSGC) defines genetic counselling as " <i>Genetic counselling is the process of helping people understand and adapt to the medical, psychological and familial implications of genetic contributions to disease. This process integrates the following: (1) Interpretation of family and medical histories to assess the chance of disease occurrence or recurrence. (2) Education about inheritance, testing, management, prevention, resources and research. (3) Counselling to promote informed choices and adaptation to the risk or condition</i> ". Genetic counselling can be provided by genetic counsellors and other health professionals (e.g. clinical geneticists, neurologists).
Genetic counsellor	Allied health professionals with a tertiary qualification specialising in the practice of genetic counselling. The US spelling "genetic counselor" is used where appropriate, such as where professional organisations or journals use this spelling.
Genetic health intervention	The term genetic health intervention is used throughout this thesis to categorise health interventions that are specifically genetic in nature, including genetic counselling and genetic testing. The aims of such health interventions are defined below.
Health intervention <sup>□</sup>	" <i>A treatment, procedure, or other action taken to prevent or treat disease, or improve health in other ways</i> ".



In vitro fertilisation with preimplantation genetic diagnosis (IVF/PGD)	IVF/PGD is an option available to couples wishing to prevent passing a known genetic condition onto their future children. Utilising IVF technology, embryos are tested prior to implantation to determine whether they have inherited the pathogenic variant(s) responsible for the genetic condition of concern, with only unaffected embryos being transferred. This technique ensures that the pathogenic variant(s) identified in a family cannot be passed on to future family members.
Outcome <sup>§</sup>	Health outcomes, referred to as 'outcomes' for brevity throughout this thesis, are <i>"the health consequences brought about by the treatment of a health condition or as a result of an interaction with the healthcare system. It is a multidimensional concept that can be studied on multiple levels."</i>
Outcome domain <sup>**</sup>	Outcome domains are defined as <i>"concepts to be measured in terms of a further specification of an aspect of health"</i> . These are less granular or overarching categories that can be used to group similar or related outcomes. For example, the domain of psychological wellbeing can be used to capture a range of specific outcomes such as anxiety, depression, and grief.
Patient	A patient is any recipient of health care services that are performed by healthcare professionals.
Patient participants	Patients who contributed to research by participating in specific aspects of a study.
Patient research partner	Patients who contributed to research as active partners in the design, conduct and analysis of a study.
Population-based RGCS	The universal offer of RGCS to the general population.
Preconception	The time period before conception of a pregnancy. In the context of RGCS, preconception offers provide the greatest number of reproductive options to couples if identified as increased risk.
Prenatal	The time period commencing from the conception of a pregnancy. In the context of RGCS, prenatal offers limit the reproductive options available in the current pregnancy at the time of testing and present additional challenges regarding timing, deliberation and informed decision-making.

Prenatal diagnosis (PND)	An invasive genetic test performed during early pregnancy to obtain a genetic sample from a fetus for genetic testing. A sample of the placenta (chorionic villus sampling) or amniotic fluid (amniocentesis) is taken transabdominally or transvaginally and tested for specific genetic conditions of concern and broadly screened for chromosomal abnormalities using a microarray. This reproductive genetic testing technique is available to increased risk couples following RGCS who wish to conceive a pregnancy naturally and test to determine the affectation status, with the option to continue or terminate an affected pregnancy in line with their personal values.
Prospective parents	This term refers to the intended parents of a future child and considers a broad range of family structures. Prospective parents may be the genetic parents of a current or future planned pregnancy or may refer to same-sex couples or other family structures where both prospective parents are not contributing genetic material to the pregnancy. The breadth of this term is intended to recognise the diverse ways in which families may be created, including the use of surrogates and donor gametes.
Reproductive genetic carrier screening (RGCS)	RGCS is a screening test carried out before pregnancy or in early pregnancy to identify a couple's chance of having a child with a serious genetic condition.
Targeted RGCS	The targeted offer of RGCS to specific groups with an increased incidence of specific genetic conditions

\* Definition taken from Resta R, Biesecker B, Bennett R, et al. A new definition of genetic counseling: National society of genetic counselors' task force report. *J Genet Counsel.* 2006;15(2):77-83. doi: <https://doi.org/10.1007/s10897-005-9014-3>

□ Definition taken from the National Institute of Health (NIH)

§ Definition taken from Lee, A., Leung, S. (2014). *Health Outcomes*. In: Michalos, A.C. (eds) Encyclopedia of quality of life and well-being research. Springer, Dordrecht. doi: [https://doi.org/10.1007/978-94-007-0753-5\\_1251](https://doi.org/10.1007/978-94-007-0753-5_1251)

\*\* Definition taken from Boers M, Kirwan JR, Wells G, et al. Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. *J Clin Epidemiol.* 2014;67(7):745-753. doi: <https://doi.org/10.1016/j.jclinepi.2013.11.013>